- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00111813
Phase 1 Study of Vorinostat and Bortezomib in Multiple Myeloma (MK-0683-015 EXT 1 (AM1))
Phase I Clinical Trial of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Advanced Multiple Myeloma
The purposes of this study are:
- To determine the maximum tolerated dose (MTD) for the combination of oral vorinostat and bortezomib in participants with advanced multiple myeloma
- To assess the safety and tolerability of this regimen and to document the participant's clinical status (by anti-tumor activity) for this combination, as determined per standard of care.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 1
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Adults with refractory or relapsed multiple myeloma
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 (a measurement to determine participant's ability to perform daily activities)
- Adequate bone marrow reserve
- Adequate hepatic and renal function
- Ability to swallow capsules
- 3 weeks or more since prior chemotherapy and have recovered from prior toxicities
Exclusion Criteria:
- Participants who plan to have a bone marrow transplant within 4 weeks of start of treatment
- Participants with prior treatment with other investigational agents with a similar anti-tumor mechanism
- Participants with other active/uncontrolled clinically significant illness
- Pregnant or nursing female participants
- Participants who received bortezomib within 3 months of start of this trial
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: vorinostat 200 mg + bortezomib 0.7 mg/m^2
Vorinostat capsules given twice daily (b.i.d.); bortezomib injection given on Days 4, 8, 11, and 15 of each cycle.
|
Vorinostat capsules.
Treatment in 21 day cycles (participants receive vorinostat for 14 days followed by a 7 day break).
Otros nombres:
Bortezomib injection.
Given twice weekly for 2 weeks with a 1 week break.
Treatment in 21 day cycles.
Otros nombres:
|
Experimental: vorinostat 200 mg + bortezomib 0.9 mg/m^2
Vorinostat capsules given b.i.d.; bortezomib injection given on Days 4, 8, 11, and 15 of each cycle.
|
Vorinostat capsules.
Treatment in 21 day cycles (participants receive vorinostat for 14 days followed by a 7 day break).
Otros nombres:
Bortezomib injection.
Given twice weekly for 2 weeks with a 1 week break.
Treatment in 21 day cycles.
Otros nombres:
|
Experimental: vorinostat 300 mg + bortezomib 1.3 mg/m^2
Vorinostat given once daily (q.d.); bortezomib given on Days 1, 4, 8, and 11 of each cycle.
|
Vorinostat capsules.
Treatment in 21 day cycles (participants receive vorinostat for 14 days followed by a 7 day break).
Otros nombres:
Bortezomib injection.
Given twice weekly for 2 weeks with a 1 week break.
Treatment in 21 day cycles.
Otros nombres:
|
Experimental: vorinostat 400 mg + bortezomib 0.9 mg/m^2
Vorinostat given q.d.; bortezomib given on Days 1, 4, 8, and 11 of each cycle.
|
Vorinostat capsules.
Treatment in 21 day cycles (participants receive vorinostat for 14 days followed by a 7 day break).
Otros nombres:
Bortezomib injection.
Given twice weekly for 2 weeks with a 1 week break.
Treatment in 21 day cycles.
Otros nombres:
|
Experimental: vorinostat 400 mg + bortezomib 1.1 mg/m^2
Vorinostat given q.d.; bortezomib given on Days 1, 4, 8, and 11 of each cycle.
|
Vorinostat capsules.
Treatment in 21 day cycles (participants receive vorinostat for 14 days followed by a 7 day break).
Otros nombres:
Bortezomib injection.
Given twice weekly for 2 weeks with a 1 week break.
Treatment in 21 day cycles.
Otros nombres:
|
Experimental: vorinostat 400 mg + bortezomib 1.3 mg/m^2
Vorinostat given q.d.; bortezomib given on Days 1, 4, 8, and 11 of each cycle.
|
Vorinostat capsules.
Treatment in 21 day cycles (participants receive vorinostat for 14 days followed by a 7 day break).
Otros nombres:
Bortezomib injection.
Given twice weekly for 2 weeks with a 1 week break.
Treatment in 21 day cycles.
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Mean Duration of Treatment With Vorinostat
Periodo de tiempo: Day 1 to an event causing discontinuation from the study, assessed up to 29 months
|
Event causing discontinuation from the study was defined as (1) progressive disease OR (2) intolerable toxicity. Progressive disease was defined as:
biopsy.
Intolerable toxicity was based on the clinical judgment of the investigator. |
Day 1 to an event causing discontinuation from the study, assessed up to 29 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Number of Participants With Dose Modifications of Either Vorinostat or Bortezomib Due to Adverse Experiences (AEs) After Treatment With Study Drug
Periodo de tiempo: Day 1 to disease progression, toxicity, or death, assessed up to 29 months
|
An adverse experience (AE) was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the sponsor's product, whether or not considered related to the use of the product.
Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the sponsor's product, was also an adverse experience.
|
Day 1 to disease progression, toxicity, or death, assessed up to 29 months
|
Mean Time to First AE Resulting in a Dose Modification in Either Vorinostat or Bortezomib
Periodo de tiempo: Day 1 to disease progression, toxicity, or death, assessed up to 29 months
|
An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the sponsor's product, whether or not considered related to the use of the product.
Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the sponsor's product, was also an adverse experience.
|
Day 1 to disease progression, toxicity, or death, assessed up to 29 months
|
Clinical AE Summary
Periodo de tiempo: Day 1 up to disease progression, toxicity, or death, assessed up to 30 days after end of treatment (up to 30 months)
|
An AE was defined as any unfavorable/unintended change in the structure/function/chemistry of the body temporally associated with the use of study drug, or any worsening of a preexisting condition. A serious AE (SAE) was any AE that resulted in death, was life threatening, resulted in a persistent or significant disability/incapacity, resulted in or prolonged an existing inpatient hospitalization, was a congenital anomaly/birth defect, was a new cancer, or was an overdose. |
Day 1 up to disease progression, toxicity, or death, assessed up to 30 days after end of treatment (up to 30 months)
|
Laboratory AE Summary
Periodo de tiempo: Day 1 up to disease progression, toxicity, or death, assessed up to 29 months
|
An AE was defined as any unfavorable/unintended change in the structure/function/chemistry of the body temporally associated with the use of study drug, or any worsening of a preexisting condition. A SAE was any AE that resulted in death, was life threatening, resulted in a persistent or significant disability/incapacity, resulted in or prolonged an existing inpatient hospitalization, was a congenital anomaly/birth defect, was a new cancer, or was an overdose. A lab (S)AE was any lab value considered clinically significant in the investigator's judgment. |
Day 1 up to disease progression, toxicity, or death, assessed up to 29 months
|
Colaboradores e Investigadores
Patrocinador
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Enfermedades cardiovasculares
- Enfermedades Vasculares
- Enfermedades del sistema inmunológico
- Neoplasias por tipo histológico
- Neoplasias
- Trastornos linfoproliferativos
- Trastornos inmunoproliferativos
- Enfermedades hematológicas
- Trastornos hemorrágicos
- Trastornos hemostáticos
- Paraproteinemias
- Trastornos de proteínas en sangre
- Mieloma múltiple
- Neoplasias De Células Plasmáticas
- Mecanismos moleculares de acción farmacológica
- Inhibidores de enzimas
- Agentes antineoplásicos
- Inhibidores de histona desacetilasa
- Bortezomib
- Vorinostat
Otros números de identificación del estudio
- 0683-015
- 2005_018
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre vorinostat
-
Peter MacCallum Cancer Centre, AustraliaGlaxoSmithKline; Merck Sharp & Dohme LLCTerminadoLinfoma folicular | Linfoma de células del manto | Linfoma de zona marginalAustralia
-
Groupe Francophone des MyelodysplasiesMerck Sharp & Dohme LLCTerminado
-
Virginia Commonwealth UniversityRetirado
-
National Center for Tumor Diseases, HeidelbergMerck Sharp & Dohme LLC; University Hospital HeidelbergTerminado
-
University of CalgaryDesconocido
-
Institut Claudius RegaudMerck Sharp & Dohme LLCTerminadoTumor sólido malignoFrancia
-
Merck Sharp & Dohme LLCYa no está disponibleLinfoma, De Células T, Cutáneo
-
Medical University of GrazTerminadoLeiomiosarcoma | Tumores del estroma endometrial | Carcinosarcomas uterinosAustria
-
German Center for Neurodegenerative Diseases (DZNE)University Hospital, Bonn; University of GöttingenTerminadoEnfermedad de AlzheimerAlemania
-
Merck Sharp & Dohme LLCTerminado